Table 6. Comparison of disease status among psoriatic arthritis patients with borderline and normal Ankle-Brachial Index values.
| Patients with borderline ABI (n=12) | Patients with normal ABI (n=39) | ||||||||
| n | % | Median | IQR | n | % | Median | IQR | p | |
| Disease duration (year) | |||||||||
| Psoriasis | 25 | 15-37 | 15 | 7-23 | 0.03 | ||||
| Psoriatic arthritis | 8.5 | 3-16 | 6 | 3-10 | 0.51 | ||||
| Disease pattern | 0.02 | ||||||||
| Peripheral disease only | 4 | 12.5 | 28 | 87.5 | |||||
| Axial disease | 8 | 42.1 | 11 | 57.9 | |||||
| Psoriasis Area and Severity Index | 2.2 | 0.55-11.5 | 1.2 | 0.1-3.3 | 0.06 | ||||
| Dactylitis score | 0 | 0-1 | 0 | 0-0 | 0.3 | ||||
| Leeds Enthesitis Index | 2.5 | 0.25-4 | 0 | 0-2 | 0.01 | ||||
| Dermatology Life Quality Index | 2 | 0.25-12 | 1 | 0-5 | 0.33 | ||||
| Health Assessment Questionnaire | 0.47 | 0.3-0.83 | 0.25 | 0.05-0.5 | 0.02 | ||||
| 68 Tender joint count counts | 4 | 0.25-19.7 | 2 | 0-4 | 0.24 | ||||
| 66 Swollen joint count counts | 0 | 0-0 | 0 | 0-0 | 0.9 | ||||
| Disease activity | <0.01 | ||||||||
| Minimal disease activity | 4 | 11.1 | 32 | 88.9 | |||||
| Active disease | 8 | 53.3 | 7 | 46.7 | |||||
| Current treatment | 0.067 | ||||||||
| NSAIDs only | 2 | 4 | |||||||
| cDMARDc | 24 | 5 | |||||||
| bDMARDs | 10 | 2 | |||||||
| cDMARDs + bDMARDs | 3 | 1 | |||||||
| ABI: Ankle-Brachial Index; IQR: Interquartile range; NSAIDs: Nonsteroidal anti-inflammatory drugs; cDMARDs: Conventional disease-modifying antirheumatic drugs; bDMARDs: Biologic disease-modifying antirheumatic drugs. | |||||||||